small molecule

OSMOPREP

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanySalix PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameOSMOPREP
Active ingredientSODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Strength0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2006
Marketing statusDISCN

Listed patents

PatentExpiresType
7687075June 2028substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OSMOPREP patent cliff — loss of exclusivity June 2028 | CliffBio